Title : Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.

Pub. Date : 2020 Aug 15

PMID : 32393603






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 PURPOSE: Differentiation syndrome (DS) is a serious adverse reaction of isocitrate dehydrogenase (IDH) inhibitors ivosidenib and enasidenib in patients with (IDH)1 and IDH2-mutated acute myeloid leukemia (AML), respectively. ivosidenib isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens
2 PURPOSE: Differentiation syndrome (DS) is a serious adverse reaction of isocitrate dehydrogenase (IDH) inhibitors ivosidenib and enasidenib in patients with (IDH)1 and IDH2-mutated acute myeloid leukemia (AML), respectively. ivosidenib isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens
3 PURPOSE: Differentiation syndrome (DS) is a serious adverse reaction of isocitrate dehydrogenase (IDH) inhibitors ivosidenib and enasidenib in patients with (IDH)1 and IDH2-mutated acute myeloid leukemia (AML), respectively. ivosidenib isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens